Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Dow
Boehringer Ingelheim
McKesson
AstraZeneca

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Patent: 10,001,483

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,001,483
Title:Methods for the treatment of Kaposi\'s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
Abstract: Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi\'s sarcoma (KS) or Kaposi\'s sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi\'s sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.
Inventor(s): Yarchoan; Robert (Bethesda, MD), Zeldis; Jerome B. (Princeton, NJ), Polizzotto; Mark N. (New South Wales, AU), Davis; David A. (Bethesda, MD), Sereti; Irini (Washington, DC), Uldrick; Thomas S. (Washington, DC), Whitby; Denise (Frederick, MD), Khetani; Vikram (Short Hills, NJ)
Assignee: Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:15/192,819
Patent Claims:see list of patent claims

Details for Patent 10,001,483

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Emd Serono Inc BAVENCIO avelumab INJECTABLE;INTRAVENOUS 761078 001 2017-05-09   Start Trial Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) 2035-06-26 RX search
Astrazeneca Uk Ltd IMFINZI durvalumab INJECTABLE;INJECTION 761069 001 2017-05-01   Start Trial Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) 2035-06-26 RX search
Emd Serono Inc BAVENCIO avelumab INJECTABLE;INJECTION 761049 001 2017-04-25   Start Trial Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) 2035-06-26 RX Orphan search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE; INJECTION 761041 001 2016-10-18   Start Trial Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) 2035-06-26 RX search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE;INJECTION 761034 001 2017-04-17   Start Trial Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) 2035-06-26 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) 2035-06-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Moodys
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.